Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 6/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 8/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sudexanox SCHEMBL29678422 | 1.00 | LTB4R (0.51) | LTB4RAKR1B1TTRLTB4R2ALOX15 | |
| SCHEMBL11771289 | 0.92 | LTB4R (0.52) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| Sudexanox SCHEMBL4414850 | 0.91 | LTB4R (0.41) | LTB4RAKR1B1TTRALOX15KDM4E | |
| SCHEMBL11769082 | 0.90 | LTB4R (0.52) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11770512 | 0.90 | LTB4R (0.52) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11769239 | 0.89 | LTB4R (0.52) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11768452 | 0.89 | LTB4R (0.52) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11772500 | 0.89 | LTB4R (0.51) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11768721 | 0.88 | LTB4R (0.50) | LTB4RAKR1B1TTRLTB4R2KDM4E | |
| SCHEMBL11770045 | 0.88 | AKR1B1 (0.62) | LTB4RAKR1B1TTRLTB4R2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486923-B2 | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | TAKEDA GMBH (DE) | 2013-07-16 | — | — | US | claimed |
| EP-2295062-B1 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | NYCOMED GMBH (DE) | 2012-08-29 | — | — | EP | claimed |
| JP-4746318-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-2295062-A1 | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | Nycomed GmbH (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-1545548-B1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | NYCOMED GMBH (DE) | 2010-06-30 | — | — | EP | claimed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| JP-2005539044-A | — | — | 2005-12-22 | — | — | JP | claimed |
| US-20050245493-A1 | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | claimed |
| EP-1545548-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA Pharma AG (DE) | 2005-06-29 | — | — | EP | claimed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | claimed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2004019955-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| US-8580143-B2 | Lyotropic chromonic liquid crystal composition, method for manufacture of lyotropic chromonic liquid crystal coating film, and lyotropic chromonic liquid crystal coating film manufactured thereby | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2013-11-12 | — | — | US | disclosed |
| US-8537304-B2 | Liquid crystal display device and manufacturing method therefor | HITACHI DISPLAYS, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8537304-B2 | Liquid crystal display device and manufacturing method therefor | HITACHI DISPLAYS, LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| EP-0014900-B1 | CARBONYLALKYL ESTERS OF PHENOXYCARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES AS WELL AS DEFOLIANTS AND DESICCANTS | BAYER AG (DE) | 1982-06-02 | — | — | EP | disclosed |
| EP-0016665-B1 | PROCESS FOR THE PREPARATION OF XANTHONE DERIVATIVES | ROUSSEL-UCLAF (FR) | 1982-05-05 | — | — | EP | disclosed |
| US-4242267-A | ACYLATING A MERCAPTOPHENOL; OXIDIZING THE SULFONIMIDOYL PHENOL; CYCLIZATION OF THE DIARYL ETHER ESTER | ROUSSEL UCLAF (FR) | 1980-12-30 | — | — | US | disclosed |
| EP-0016665-A1 | Process for the preparation of xanthone derivatives | ROUSSEL-UCLAF (FR) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | LTB4R 92/4885AKR1B1 905/4885TTR 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.